Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - alendronate sodium -

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - alendronate sodium trihydrate 52.21mg equivalent to 40 mg alendronic acid - tablet - 40 mg - active: alendronate sodium trihydrate 52.21mg equivalent to 40 mg alendronic acid excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax is indicated: · in postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). · in postmenopausal women who are at risk of developing osteoporosis fosamax is indicated for the prevention of osteoporosis to reduce the risk of future fracture. · for the treatment of osteoporosis in men to prevent fractures. · for the treatment and prevention of glucocorticoid-induced osteoporosis in men, premenopausal women and postmenopausal women receiving oestrogen. · for treatment of paget's disease of bone in men and women.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - alendronate sodium trihydrate 6.53mg equivalent to 5 mg of alendronic acid - tablet - 5 mg - active: alendronate sodium trihydrate 6.53mg equivalent to 5 mg of alendronic acid excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax is indicated: · in postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). · in postmenopausal women who are at risk of developing osteoporosis fosamax is indicated for the prevention of osteoporosis to reduce the risk of future fracture. · for the treatment of osteoporosis in men to prevent fractures. · for the treatment and prevention of glucocorticoid-induced osteoporosis in men, premenopausal women and postmenopausal women receiving oestrogen. · for treatment of paget's disease of bone in men and women.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronic acid - tablet - 70 mg - active: alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronic acid excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax is indicated: · in postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). · in postmenopausal women who are at risk of developing osteoporosis fosamax is indicated for the prevention of osteoporosis to reduce the risk of future fracture. · for the treatment of osteoporosis in men to prevent fractures. · for the treatment and prevention of glucocorticoid-induced osteoporosis in men, premenopausal women and postmenopausal women receiving oestrogen. · for treatment of paget's disease of bone in men and women.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronate anhydrous free acid; colecalciferol 140ug equivalent to 5600 iu;   - tablet - 70/140 - active: alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronate anhydrous free acid colecalciferol 140ug equivalent to 5600 iu   excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax plus is indicated for the treatment of osteoporosis in select patients where vitamin d supplementation is recommended.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to to 70 mg anhydrous free acid; colecalciferol 70ug equivalent to 2800 iu;   - tablet - 70/70 - active: alendronate sodium trihydrate 91.37mg equivalent to to 70 mg anhydrous free acid colecalciferol 70ug equivalent to 2800 iu   excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax plus is indicated for the treatment of osteoporosis in select patients where vitamin d supplementation is recommended.

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - alendronate sodium - tablet - 70 milligram(s) - bisphosphonates; alendronic acid - bisphosphonate, for the treatment of bone diseases - it is indicated in adults for the treatment of postmenopausal osteoporosis. fosamax reduces the risk of vertebral and hip fractures.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - alendronate sodium trihydrate 13.05mg equivalent to 10 mg alendronic acid - tablet - 10 mg - active: alendronate sodium trihydrate 13.05mg equivalent to 10 mg alendronic acid excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - alendronate sodium 91.37 mg eqv alendronic acid; cholecalciferol 140 mcg eqv vitamin d - tablet - 70mg - alendronate sodium 91.37 mg eqv alendronic acid 70mg; cholecalciferol 140 mcg eqv vitamin d 5600 iu

Singapore - English - HSA (Health Sciences Authority)

organon singapore pte. ltd. - alendronate sodium 91.37 mg eqv alendronic acid; cholecalciferol 70 mcg eqv vitamin d - tablet - 91.37 mg - alendronate sodium 91.37 mg eqv alendronic acid 70 mg; cholecalciferol 70 mcg eqv vitamin d 2800 iu